Symbol="IKT"
AssetType="Common Stock"
Name="Inhibikase TherapeuticsÂ Inc"
Description="Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia."
CIK="1750149"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA, GA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="14946000"
EBITDA="-18121884"
PERatio="None"
PEGRatio="None"
BookValue="4.892"
DividendPerShare="0"
DividendYield="0"
EPS="-4.05"
RevenuePerShareTTM="0.033"
ProfitMargin="0"
OperatingMarginTTM="-128.25"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.603"
RevenueTTM="141930"
GrossProfitTTM="-8258499"
DilutedEPSTTM="-4.05"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.402"
AnalystTargetPrice="27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="219.63"
PriceToBookRatio="0.492"
EVToRevenue="2.748"
EVToEBITDA="0.733"
Beta="0.826"
num_52WeekHigh="7.26"
num_52WeekLow="2.64"
num_50DayMovingAverage="3.706"
num_200DayMovingAverage="3.938"
SharesOutstanding="5300000"
DividendDate="None"
ExDividendDate="None"
symbol="IKT"
open="2.80"
high="2.82"
low="2.63"
price="2.68"
volume="19148.00"
latest_trading_day="2023-07-17"
previous_close="2.82"
change="-0.14"
change_percent="-4.9645%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="67"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="33"
Volume_recent_avg="218861"
Change_recent_avg="-0.01"
Delta_recent_avg="0.09"
Variance_recent_avg="0.05"
Change_ratio_recent_avg="-0.86"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="33"
Aroon_momentum_negative="67"
image_negative_thumbnail_id_1="518"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0087.jpeg"
image_negative_thumbnail_id_2="161"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0015.jpeg"
image_neutral_thumbnail_id_1="577"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0022.jpeg"
image_neutral_thumbnail_id_2="546"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0053.jpeg"
image_positive_thumbnail_id_1="602"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0106.jpeg"
image_positive_thumbnail_id_2="699"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0009.jpeg"
image_professor_thumbnail_id_1="1175"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
image_professor_thumbnail_id_2="1180"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
